se of the NMF Biomarker as Predictive Diagnostic for Effective Use of Cyclosporine and Dupilumab in the Treatment of Atopic Dermatitis

Erasmus MC0 个研究点目标入组 318 人开始时间: 待定最近更新: 2024年2月28日

适应症

试验速览

暂无简介。

•Children and adolescents, aged between 2 and 18, with moderate to severe atopic dermatitis (diagnosed according to the UK working party criteria)
•-Patients and parents/guardians able to participate in the study and willing to give written informed consent
•-EASI (Eczema Area Severity Index) = 6 at screening and baseline (corresponding with moderate-to-severe disease)
•-IGA (Investigators Global Assessment) = 3 at screening and baseline (corresponding with moderate-to-severe disease)

•-children under the age of 2 years (due to the prescribe conditions of CsA) and patients older than 18 years
•-contraindication for CsA or dupilumab
•-use of topical corticosteroids (TCS) or topical calcineurine inhibitors (TCI) 2 weeks before randomization (during the washout period)
•-use of systemic anti-inflammatory medication 4 weeks before randomization
•-patient (or one of the parents/guardians) not willing to be randomized
•-children with a history of any known primary immunodeficiency disorder
•-children with a history of cancer
•-EASI < 6 at screening or at baseline
•-IGA <3 at screening or at baseline

发起方